[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100365848":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":89,"collaborators":25,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":93,"sex":99,"minAge":100,"maxAge":25,"enrollmentInfo":101,"targetDuration":25,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":25,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Insel Gruppe AG, University Hospital Bern","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"high sodium infusion fluid","ACTIVE_COMPARATOR","Patients will exclusively receive 0.9% saline (sodium content 154mmol\u002Fl) for fluid maintenance and resuscitation from study inclusion until ICU\u002Fintermediate care (IMC) discharge.",[13],"Drug: 0.9% Sodium-chloride",{"label":15,"type":10,"description":16,"interventionNames":17},"low sodium infusion fluid","Patients will exclusively receive lactated Ringer's (sodium content 130mmol\u002Fl) for fluid maintenance and resuscitation from study inclusion until ICU\u002Fintermediate care (IMC) discharge.",[18],"Drug: Ringer's Lactate",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","0.9% Sodium-chloride","We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.",[9],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Ringer's Lactate",[15],[30],{"name":31,"affiliation":32,"role":33},"Anna S Messmer, MD","Department of Intensive Care, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland","PRINCIPAL_INVESTIGATOR",[35,40],{"name":31,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","+41316322111","0041","anna.messmer@insel.ch",{"name":41,"role":36,"phone":37,"phoneExt":38,"email":42},"Research Nurses Department of Intensive Care","kim.researchnurses@insel.ch",[44,63,75],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Department of perioperative Intensive Care Medicine","RECRUITING","Sankt Gallen","Canton of St. Gallen","9007","Switzerland","CH",{"type":53,"coordinates":54},"Point",[55,56],9.37477,47.42391,{"lat":56,"lon":55},[59],{"name":60,"role":36,"phone":61,"phoneExt":25,"email":62},"Urs Pietsch, PD Dr. med.","+41 71 494 93 21","urs.pietsch@kssg.ch",{"facility":64,"status":46,"city":65,"state":25,"zip":66,"country":50,"countryCode":51,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland","Bern","3010",{"type":53,"coordinates":68},[69,70],7.44744,46.94809,{"lat":70,"lon":69},[73],{"name":31,"role":36,"phone":74,"phoneExt":25,"email":39},"0041316322111",{"facility":76,"status":46,"city":77,"state":25,"zip":78,"country":50,"countryCode":51,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Department of Intensive Care Medicine","Geneva","1205",{"type":53,"coordinates":80},[81,82],6.14569,46.20222,{"lat":82,"lon":81},[85],{"name":86,"role":36,"phone":87,"phoneExt":25,"email":88},"Hervé Quintard, Prof. Dr. med.","+41 223727460","Herve.Quintard@hcuge.ch",{"type":90,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100365848","crystalloid-fluid-choice-and-neurological-outcome-in-patients-after-subarachnoid-haemorrhage-100365848",false,"NCT04043598","Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage","Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage - a Multi-center Randomized Double-blind Clinical Trial","CRYSTALLBrain","Inclusion Criteria:\n\nAll adult patients suffering from non-traumatic subarachnoid haemorrhage.\n\nExclusion Criteria:\n\n* Patients with major intra-cranial trauma\n* Diagnosis of an AV-malformation as the source of subarachnoid hemorrhage on the primary CT\u002FMRI or angiography\n* More than 24 hours after diagnosis of subarachnoid haemorrhage as diagnosed by cerebral imaging (CT scan or MRI)\n* Patients with clear limitation to therapy at hospital admission (eg ICU admission for evaluation of organ donation)\n* Declining of informed consent","ALL","16 Years",{"count":102,"type":103},320,"ESTIMATED","INTERVENTIONAL",[106],"NA","Patients with subarachnoid hemorrhage are prone to suffer from dysnatriemia. Evidence shows that hyponatriemia is associated with increased incidence of vasospasm, brain swelling and mortality in these patients. Patients with subarachnoid hemorrhage often require large amounts of iv fluids in order to maintain euvolemia and support cardiocirculatory function. Prior evidence shows that the type of infusion fluid significantly influences blood sodium content. Hence, this study evaluated whether the sodium content of the infusion solution impacts mortality and morbidity in patients with subarachnoid hemorrhage.",[109,110,111,112],"Subarachnoid Hemorrhage","Critical Illness","Infusion Fluid","Sodium Disorder","2026-04-28",{"date":115,"type":116},"2026-04-29","ACTUAL",{"date":118,"type":116},"2022-05-24",{"date":120,"type":103},"2027-12",{"name":5,"class":6},3]